Androstenedione

BOSTON —In this video exclusive, Richard J. Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.

BOSTON — Crinecerfont lowered androstenedione levels and allowed for lower glucocorticoid doses for children with classic congenital adrenal hyperplasia, according to findings from the CAHtalyst Pediatric phase 3 trial.

BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control compared with placebo, researchers reported.

An investigational nonsteroidal treatment for classic congenital adrenal hyperplasia improved levels of androstenedione and testosterone for a small cohort of men with the condition, according to data from a phase 2 study.